Eligibility:
The international Galien award for pharmaceutical research is organized every second year, and is given to recently marketed drugs that have been won a national award. See below the list of the potential submissions with the country where they have been awarded.
Product (trade name, Company) Countries Nitisinon (Orfadin, Swedish Orphan International) GERMANY Ranibizumab (Lucentis, Novartis Pharma) BELGIUM Rivaroxaban (Xarelto, Bayer-Schering) BELGIUM Ivabradine (Procoralan, Servier) SPAIN/ FRANCE/ITALY /GERMANY Trabectidin (Yondelis, PharmaMar) SPAIN Adalimumab (Humira, Abbott) U.S.A. Sitagliptine (Januvia, M.S.D.CHIBRET) U.S.A./THE NETHERLANDS Raldegravir (Isentress, Merck) U.S.A./FRANCE/ITALY Varénicline (Chantix, Pfizer) U.S.A. Maraviroc (Selzentry, Pfizer) U.S.A./THE NETHERLANDS Eculizumab (Soliris, Alexion) U.S.A./FRANCE RhBMP-2 (Infuse, Wyeth) U.S.A. Eltrombopag (Promacta,GSK) U.S.A. Romiplostim (Nplate, Amgen) U.S.A. Sorafénib (Nexavar, Bayer-Shering Pharma)) FRANCE Stiripentol (Diacomit, Biocodex) FRANCE Natalizumab (Tysabri, Biogen Idec). FRANCE Omalizumab (Xolair, Novartis Pharma) ITALY Sitagliptine (Januvia, M.S.D.CHIBRET) U.S.A./THE NETHERLANDS Cervarix (GlaxoSmithKline) UNITED KINGDOM Déférasirox (Exjade,Novartis) UNITED KINGDOM Abatacept (Orencia, BMS) SWITZERLAND Submissions:
A separate entry form must be completed for each drug or device entered.
Requirements:
Please submit the following information for each drug submitted:
- Therapeutic Category(s)
- Background info/need for drug/device
- History of product development
- Why product is innovative
- Pubmed references
You will be provided an upload form for each topic in order to enhance your submission file.
Technical note:
Your browser software must accept cookies in order to enter the secured area of the site.
You can usually set it up in the Security tab of the Preferences panel of your browser.
|
Not yet registered?
|
